Informationen:
Fehler:
ID
18125
Beschreibung
Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00494338
Link
https://clinicaltrials.gov/show/NCT00494338
Stichworte
Versionen (1)
- 21.10.16 21.10.16 -
Hochgeladen am
21. Oktober 2016
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Metastatic Prostate Cancer NCT00494338
Eligibility Metastatic Prostate Cancer NCT00494338
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Metastatic Prostate Cancer NCT00494338
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Androgen Insensitive Prostatic Neoplasms Metastatic
Item
patients with histologically confirmed maipc
boolean
C3658267 (UMLS CUI [1,1])
C0036525 (UMLS CUI [1,2])
C0036525 (UMLS CUI [1,2])
Progressive Disease bone | Progressive Disease soft tissue | Prostate-Specific Antigen | Testosterone level
Item
documented progressive disease in bone, soft tissue or psa despite castrate levels of testosterone
boolean
C1335499 (UMLS CUI [1,1])
C0262950 (UMLS CUI [1,2])
C1335499 (UMLS CUI [2,1])
C0225317 (UMLS CUI [2,2])
C0138741 (UMLS CUI [3])
C0428412 (UMLS CUI [4])
C0262950 (UMLS CUI [1,2])
C1335499 (UMLS CUI [2,1])
C0225317 (UMLS CUI [2,2])
C0138741 (UMLS CUI [3])
C0428412 (UMLS CUI [4])
Luteinizing Hormone-releasing Hormone Agonist
Item
if lhrh agonist were used previously it must be kept
boolean
C1518041 (UMLS CUI [1])
Androgen Antagonists | Flutamide | Cyproterone
Item
previous anti-androgen should be held at least 4 weeks for flutamida or cyproterone and 6 weeks for bycalumida
boolean
C0002842 (UMLS CUI [1])
C0016384 (UMLS CUI [2])
C0010621 (UMLS CUI [3])
C0016384 (UMLS CUI [2])
C0010621 (UMLS CUI [3])
Diethylstilbestrol
Item
previous des should be held for at least 4 weeks before partcipating in the trial
boolean
C0012203 (UMLS CUI [1])
Chemotherapy naive
Item
chemotherapy naive patients
boolean
C3665472 (UMLS CUI [1,1])
C0919936 (UMLS CUI [1,2])
C0919936 (UMLS CUI [1,2])
Radioisotopes
Item
no prior radioisotope
boolean
C0034595 (UMLS CUI [1])
Palliative course of radiotherapy Bone Marrow Percentage
Item
less than 25% of bone marrow should be irradiated for prior palliative radiotherapy
boolean
C0475092 (UMLS CUI [1,1])
C0005953 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
C0005953 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
Karnofsky Performance Status
Item
kps> 70%
boolean
C0206065 (UMLS CUI [1])
Hematologic function | Liver function | Renal function
Item
adequate hematologic, hepatic and renal function
boolean
C0221130 (UMLS CUI [1])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
Illness Serious
Item
patients with serious medical illness
boolean
C0221423 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0205404 (UMLS CUI [1,2])
Heart Disease Significant
Item
history of significant active cardiac disease
boolean
C0018799 (UMLS CUI [1,1])
C0750502 (UMLS CUI [1,2])
C0750502 (UMLS CUI [1,2])
Gastrointestinal ulceration | Gastrointestinal Hemorrhage | Gastrointestinal perforation
Item
history of gastrointestinal ulceration, bleeding or perforation
boolean
C1963975 (UMLS CUI [1])
C0017181 (UMLS CUI [2])
C0151664 (UMLS CUI [3])
C0017181 (UMLS CUI [2])
C0151664 (UMLS CUI [3])
Myocardial Infarction
Item
history of myocardial infarctin within past 12 months
boolean
C0027051 (UMLS CUI [1])
Allergy to sulfonamides | Hypersensitivity celecoxib | Urticaria Due to NSAIDS
Item
allergy to sulfonamides or to celecoxib or history of urticaria to any nsaid
boolean
C0038757 (UMLS CUI [1])
C0020517 (UMLS CUI [2,1])
C0538927 (UMLS CUI [2,2])
C0042109 (UMLS CUI [3,1])
C0678226 (UMLS CUI [3,2])
C0003211 (UMLS CUI [3,3])
C0020517 (UMLS CUI [2,1])
C0538927 (UMLS CUI [2,2])
C0042109 (UMLS CUI [3,1])
C0678226 (UMLS CUI [3,2])
C0003211 (UMLS CUI [3,3])
Study Subject Participation Status
Item
the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
boolean
C2348568 (UMLS CUI [1])